The first update to guidance on pharmacological management of obesity and its complications, issued by the European Association for the Study of Obesity (EASO) and published in Nature Medicine, adds new evidence from multiple randomised clinical trials. The updated ‘algorithm’ is presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May).

New research presented at this year’s European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide are seven times more likely to maintain that weight loss by continuing on MTD than those who stop treatment, while those who switch to a lower dose of 5 mg are four times more likely to maintain weight loss than those who stop. The study is by Dr Deborah Horn, Director of the Center for Obesity Medicine and Metabolic Performance at McGovern Medical School at UTHealth Houston, Houston, Texas, USA, and colleagues. The study was funded by Eli Lilly and Company, the manufacturer of tirzepatide.

New research presented at this year’s European Congress on Obesity (ECO2026) in Istanbul, Turkey (12-15 May) and published in Nature Medicine shows that most weight loss achieved using the injectable obesity drugs tirzepatide or semaglutide can be maintained by switching to daily oral orforglipron treatment. The study is by Dr Louis J. Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine, New York, New York, USA, and colleagues, and is sponsored by Eli Lilly and Company, the manufacturer of tirzepatide and orforglipron.

The discovery of their leading drug candidate, named T111, has been 15 years in the making and has the potential to become a single-encounter malaria drug that would simplify treatment, prevent relapses that drive ongoing transmission and contribute meaningfully to malaria elimination efforts.